The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant nivolumab plus paclitaxel/cisplatin- chemo-radiotherapy (neo-NTP-CRT) followed by esophagectomy for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II study.
 
Ta-Chen Huang
No Relationships to Disclose
 
Jhe-Cyuan Guo
Honoraria - Astellas Pharma; Bayer; Ipsen; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech
Consulting or Advisory Role - Astellas Pharma; Merck Serono; Ono Pharmaceutical
Travel, Accommodations, Expenses - Ipsen; MSD; Novartis; Ono Pharmaceutical
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Abbvie; Anbogen Therapeutics; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; IMPAC Medical Systems; Novartis; PharmaEngine
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; IMPAC Medical Systems; Lilly
 
Hung-Yang Kuo
No Relationships to Disclose
 
Chien Huai Chuang
No Relationships to Disclose
 
Jason, Chia-Hsien Cheng
No Relationships to Disclose
 
Feng-Ming Hsu
No Relationships to Disclose
 
Jang-Ming Lee
No Relationships to Disclose
 
Pei-Ming Huang
No Relationships to Disclose
 
Kuan-Yin Ko
No Relationships to Disclose
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Ipsen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche